<DOC>
	<DOC>NCT01732848</DOC>
	<brief_summary>The purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials</brief_summary>
	<brief_title>A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy and hepatitis C virus (HCV)infected subjects who participated in prior Phase 1 trial with BMS986094/INX08189 and: 1. Received at least 1 dose of INX08189 or 2. Received placebo in studies for HCVinfected subjects (INH189002 or INH189006) Age 18 or older</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Volunteers</keyword>
</DOC>